Form 4: Oncocyte Corp Director Andrew J. Last Acquires Options
SEC Form 4
Director Andrew J. Last acquired options to purchase 30,000 shares of Oncocyte Corp common stock on July 1, 2024.
Summary
- On July 1, 2024, Andrew J. Last, a director of Oncocyte Corp, acquired options to purchase 30,000 shares of the company's common stock.
- The exercise price of these options is $2.95 per share.
- The options vest one year from the grant date, contingent upon Last's continued service as a director until the vesting date or the next annual shareholder meeting, whichever is earlier.
- The options expire on July 1, 2034.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reflects a routine transaction related to executive compensation.
Industry Context
This filing reflects standard executive compensation practices within publicly traded companies, where stock options are frequently used to align the interests of directors and shareholders.
Stakeholder Impact
- The acquisition of options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 07/01/2024 | Date of transaction: Andrew J. Last acquired options to purchase common stock. |
| 07/01/2024 | Options become exercisable one year from this date, subject to continued service. |
| 07/03/2024 | Date of signature for the Form 4 filing. |
| 07/01/2034 | Expiration date of the options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.